China, Aug. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Optimal Therapeutic Strategies Following ADC Resistance in Advanced HER2-Low Breast Cancer: A Multicenter Retrospective Real-World Study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600129759
Registration Time: 2026/08/10
Type: Observational study
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=332188
Published by HT Digital Content Services with permission from Health Daily Digest....